Bill Anderson, Bayer CEO (Photographer: Krisztian Bocsi/Bloomberg via Getty Images)
November 22, 2023 11:35 AM ESTUpdated November 27, 05:05 AM
Pharma

Bay­er’s turn­around plan: Fo­cus on spe­cial­ty drugs, low­er costs and few­er big bets

Ayisha Sharma

News Reporter

Af­ter a se­ries of bru­tal set­backs that have chopped Bay­er’s mar­ket val­ue by around 21% in the last month, the Ger­man drug­mak­er un­veiled an over­hauled …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times